Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Nature Biotechnology

Volumn 34, Issue 11, 2016, Pages 1161-1167

  Stevens, Mark M ^a   Maire, Cecile L ^b   Chou, Nigel ^a,c   Murakami, Mark A ^c   Knoff, David S ^b   Kikuchi, Yuki ^a,d   Kimmerling, Robert J ^a,c   Liu, Huiyun ^b   Haidar, Samer ^b   Calistri, Nicholas L ^a   Cermak, Nathan ^a   Olcum, Selim ^a   Cordero, Nicolas A ^b   Idbaih, Ahmed ^e,f   Wen, Patrick Y ^b   Weinstock, David M ^b,g   Ligon, Keith L ^b,g,h,i   Manalis, Scott R ^a,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Massachusetts Institute of Technology   (United States)

^d HITACHI HIGH TECHNOLOGIES CORPORATION   (Japan)

^e SORBONNE UNIVERSITÉ   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; CELL CULTURE; CYTOLOGY; DISEASES; TUMORS;

CANCER THERAPEUTICS; CELL VIABILITY; DRUG SENSITIVITY; FUNCTIONAL ASSAYS; LYMPHOCYTIC LEUKEMIA; MASS ACCUMULATION RATES; PERIPHERAL BLOOD; SUSPENDED MICROCHANNEL RESONATORS;

CELLS;

BIOLOGICAL MARKER; CYTARABINE; IMATINIB; MIDOSTAURIN; PONATINIB; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B-CELL LEUKEMIA CELL LINE; CANCER CELL; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SUBPOPULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MASS ACCUMULATION RATE; NONHUMAN; PARAMETERS; PHENOTYPE; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR RESISTANCE; CELL CULTURE; DEVICE FAILURE ANALYSIS; DEVICES; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; EQUIPMENT DESIGN; LAB ON A CHIP; MICROELECTROMECHANICAL SYSTEM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HUMANS; LAB-ON-A-CHIP DEVICES; MICRO-ELECTRICAL-MECHANICAL SYSTEMS; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84994879687     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3697     Document Type: Article

References (31)

1. Mellinghoff, I.K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
2. Sos, M.L. et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727-1740 (2009).
3. Garraway, L.A. & Jänne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
4. Klempner, S.J., Myers, A.P. & Cantley, L.C. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 3, 1345-1354 (2013).
5. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389-393 (2013).
6. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
7. Francis, J.M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956-971 (2014).
8. Burstein, H.J. et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 29, 3328-3330 (2011).
9. Friedman, A.A., Letai, A., Fisher, D.E. & Flaherty, K.T. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15, 747-756 (2015).
10. Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
11. Burg, T.P. et al. Weighing of biomolecules, single cells and single nanoparticles in fuid. Nature 446, 1066-1069 (2007).
12. Godin, M. et al. Using buoyant mass to measure the growth of single cells. Nat. Methods 7, 387-390 (2010).
13. Son, S. et al. Direct observation of mammalian cell growth and size regulation. Nat. Methods 9, 910-912 (2012).
14. Byun, S., Hecht, V.C. & Manalis, S.R. Characterizing Cellular Biophysical Responses to Stress by Relating Density, Deformability, and Size. Biophys. J. 109, 1565-1573 (2015).
15. Wu, S. et al. Quantifcation of cell viability and rapid screening anti-cancer drug utilizing nanomechanical fuctuation. Biosens. Bioelectron. 77, 164-173 (2016).
16. Lathia, J.D. et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One 6, e24807 (2011).
17. Deleyrolle, L.P. et al. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134, 1331-1343 (2011).
18. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
19. Pui, C.H., Relling, M.V. & Downing, J.R. Acute lymphoblastic leukemia. N. Engl. J. Med. 350, 1535-1548 (2004).
20. Cortes, J.E. et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367, 2075-2088 (2012).
21. Verreault, M. et al. Preclinical effcacy of the MDM2 inhibitor RG7112 in MDM2-amplifed and TP53 wild-type glioblastomas. Clin. Cancer Res. 22, 1185-1196 (2015).
22. Jeay, S. et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. eLife 4 http://dx.doi.org/10.7554/eLife.06498 (published online 12 May 2015).
23. Andreeff, M. et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin. Cancer Res. 22, 868-876 (2016).
24. Lane, A.A. et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat. Genet. 46, 618-623 (2014).
25. Pencina, M.J., D'Agostino, R.B. Sr., D'Agostino, R.B. Jr. & Vasan, R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifcation and beyond. Stat. Med. 27, 157-172, discussion 207-212 (2008).
26. Cermak, N. et al. High-throughput growth measurements on single cells via serial microfuidic mass sensor arrays. Nat. Biotechnol. http://dx.doi.org/10.1038/nbt.3666 (2016).
27. Fischer, T. et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol. 28, 4339-4345 (2010).
28. Shalek, A.K. et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 510, 363-369 (2014).
29. Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977-989 (2015).
30. Jonas, O. et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 7, 284ra57 (2015).
31. Klco, J.M. et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121, 1633-1643 (2013).